Analytical method for beta-amyloid protein pathology by using thioflavine T staining

Abstract

The invention relates to an analytical method for beta-amyloid protein pathology by using thioflavine T staining. The method comprises the following processes: A, a patient pathological specimen source, B, an experimental animal pathological specimen source, C, treatment of patient and experimental animal brain tissue specimens, D, immumohistochemical staining of specimen beta-amyloid protein 1-42, E, thioflavine T staining of the specimen, and F, optical / fluorescence microscope pathological examination. The method has the advantages of introducing and widely using the thioflavine T to mark an amyloid protein disease patient brain tissue pathological specimen and assess the pharmacological intervention effect of alzheimer disease (AD) transgenic animals; compared with the traditional silver staining method and A beta immunohistochemical method, the method provided by the invention has the characteristics of being simple and feasible, and sensitive and reliable, is beneficial for clearing the nosetiology of cerebral hemorrhage, and has great guide value on formulation of patient secondary intervening measures. The wide application of the technology has a powerful promoting effect on clinical pathological research and translational medicine research of the A beta related diseases (alzheimer disease and amyloid angiopathy).

Description

technical field [0001] The invention relates to a method for pathological diagnosis of beta-amyloid protein disease by thioflavin T staining. The invention belongs to the technical field of using Thioflavin T (ThT) to mark β-amyloid protein to carry out the specific diagnosis of brain histopathological specimens and brain histopathology of Alzheimer's disease (AD) and amyloid cerebrovascular disease patients. Background technique [0002] The pathological diagnosis of AD often relies on the traditional silver staining method, which is cumbersome and requires high technical requirements; Aβ immunohistochemical detection began in the 1980s due to the different recognition rates of various antibodies, which requires high specificity of antibodies. And the operation steps are relatively cumbersome, which limits its application to a certain extent; until the National Institute on Aging-Alzheimer's Disease Association (NIA-AA) revised the pathological diagnostic criteria of AD in ...

AI Technical Summary

Problems solved by technology

[0002]The pathological diagnosis of AD often relies on the traditional silver staining method, which is cumbersome and technically demanding; The recognition rate of different antibodies is different, the specificity requirements for antibodies are high, and the operation steps are relatively cumbersome, which limits its application to a certain extent; The specific Aβ antibody diagnosis is only recommended after the revision of the pathological diagnostic criteria for AD, but there are still problems such as high cost, long time-consuming, and unstable detection results